Positrigo Secures 7 Million CHF in Oversubscribed Financing Round

Positrigo, a Swiss company specializing in nuclear medical devices for brain imaging, has successfully completed a 7 million CHF financing round which it exceeded initial expectations. HealthCap, a prominent European venture capital firm focused on life sciences, led this round alongside other investors including Navivo and existing shareholders. This funding will expedite Positrigo's production and commercial efforts, particularly the rollout of NeuroLF, their innovative brain PET device, in the U.S. and European markets. The announcement also marks the appointment of new board members with significant expertise in the healthcare industry, including Max Odlander from HealthCap, Didier Deltort, and Dr. Ajit Singh. Three existing board members, who played pivotal roles during Positrigo's research and development phase, will not seek re-election but will continue to support the company in other capacities. The NeuroLF system addresses a crucial market need, especially for Alzheimer's diagnosis, predicted to affect 150 million individuals by 2050. Positrigo, founded in 2018, is a spin-off from ETH Zurich and has achieved key regulatory approvals in the US and EU for its medical imaging technology.